2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Wednesday, November 8, 2017

11:00AM-12:30PM: Abstract Number: 2976

Identification of Systemic Lupus Erythematosus Causal Risk Variant Candidates Spanning the UBE2L3 Haplotype

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis II

11:00AM-12:30PM: Abstract Number: 2946

Identifying Rapid Structural Disease Progression in Knee Osteoarthritis

Osteoarthritis – Clinical Aspects II: Structural Progression and Incidence

11:00AM-12:30PM: Abstract Number: 2966

Impact of Tofacitinib Treatment Compared with Placebo or Methotrexate on Cardiovascular Risk Scores in Six Phase 3 Randomized Controlled Trials

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy V: Imaging and Cardiovascular Outcomes Therapy

11:00AM-12:30PM: Abstract Number: 2945

Incident Hand OA Is Strongly Associated with Reduced Peripheral Blood Leukocyte Telomere Length

Osteoarthritis – Clinical Aspects II: Structural Progression and Incidence

11:00AM-12:30PM: Abstract Number: 2970

Inhibition of Radiographic Progression in Psoriatic Arthritis By Adalimumab Independent of the Control of Clinical Disease Activity

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment V

11:00AM-12:30PM: Abstract Number: 2991

Is a Growing Waistline over 8 Years Associated with Incident Functional Limitation and Low Health-Related Quality of Life in Knee Osteoarthritis?

ARHP Epidemiology and Public Health

11:00AM-12:30PM: Abstract Number: 2990

Is Risk of Retinopathy Among Hydroxychloroquine Users of SLE Patients Accurate? a Simulation Study Accounting for Competing Risk of Death

ARHP Epidemiology and Public Health

11:00AM-12:30PM: Abstract Number: 2938

Is Synovial Hypertrophy without Doppler Activity in Rheumatoid Arthritis Joints Sensitive to Change ? – Results of a Longitudinal Ultrasound Study

Imaging of Rheumatic Diseases II: Focus on Rheumatoid Arthritis and Systemic Sclerosis

11:00AM-12:30PM: Abstract Number: 2968

Less Fatigue in Psoriatic Arthritis after High Intensity Interval Training. a Randomized Controlled Trial

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment V

11:00AM-12:30PM: Abstract Number: 2987

Moderate and Serious Psychological Distress Among US Adults with and without Arthritis, 2002 to 2015

ARHP Epidemiology and Public Health

11:00AM-12:30PM: Abstract Number: 2977

Molecular Phenotypes Associated with Clinical Disease Activity in Adult Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis II

11:00AM-12:30PM: Abstract Number: 2982

Morbidity and Mortality of Scleroderma in African Americans

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics III

11:00AM-12:30PM: Abstract Number: 2962

MRI Results Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy V: Imaging and Cardiovascular Outcomes Therapy

11:00AM-12:30PM: Abstract Number: 2965

Non-Invasive Imaging Methods for Evaluating the Cardiovascular Involvement in Patients with Rheumatoid Arthritis before and after 18 Months of Treatment with Anti-TNF Drugs

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy V: Imaging and Cardiovascular Outcomes Therapy

11:00AM-12:30PM: Abstract Number: 2986

Omega Polyunsaturated Fatty Acids and Systemic Lupus Erythematosus (SLE): the Michigan Lupus Epidemiology & Surveillance (MILES) Program

ARHP Epidemiology and Public Health

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].